1 / 9

GLP-1 Receptor Agonist Lowers Glucose with Reduced Hypoglycemia Risk in HNF1A Diabetes

This study investigates the effectiveness and safety of GLP-1 receptor agonists (liraglutide) compared to sulfonylureas (glimepiride) in patients with HNF1A diabetes. Over six weeks, 16 patients received both treatments in a double-blind, randomized, crossover trial. Results showed that both drugs lowered fasting plasma glucose and postprandial glucose levels without significant differences in efficacy. However, liraglutide was associated with a much lower incidence of hypoglycemia compared to glimepiride, highlighting its potential as a safer treatment option.

juana
Download Presentation

GLP-1 Receptor Agonist Lowers Glucose with Reduced Hypoglycemia Risk in HNF1A Diabetes

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Featured Article: Glucose-Lowering Effects and Low Risk of Hypoglycemia in Patients With Maturity-Onset Diabetes of the Young When Treated With a GLP-1 Receptor Agonist: ADouble- Blind, Randomized, Crossover Trial Signe H. Østoft, Jonatan I. Bagger, Torben Hansen, Oluf Pedersen, Jens Faber, Jens J. Holst, Filip K. Knop, and Tina Vilsbøll Diabetes Care Volume 37: 1797-1805 July, 2014

  2. STUDY OBJECTIVE • Hepatocyte nuclear factor 1 (HNF1A diabetes) is often treated with sulfonylureas that confer a high risk of hypoglycemia • We evaluated treatment with GLP-1 receptor agonists (GLP-1RAs) in patients with HNF1A diabetes Østoft S. H. et al. Diabetes Care 2014;37:1797-1805

  3. STUDY DESIGN AND METHODS • 16 patients with HNF1A diabetes received 6 weeks of treatment with a GLP-1RA (liraglutide) and placebo (tablets), as well as a sulfonylurea (glimepiride) and placebo (injections) • Glimepiride was up-titrated once weekly in a treat-to-target manner • Liraglutide was up-titrated once weekly to 1.8 mg once daily • At baseline and at the end of each treatment period, a standardized liquid meal test was performed, including a 30-min light bicycle test Østoft S. H. et al. Diabetes Care 2014;37:1797-1805

  4. Østoft S. H. et al. Diabetes Care 2014;37:1797-1805

  5. RESULTS • Fasting plasma glucose (FPG) decreased during the treatment periods, with no difference between treatments • Postprandial plasma glucose (PG) responses were lower with both glimepiride and liraglutide compared with baseline, with no difference between treatments • 18 episodes of hypoglycemia occurred during glimepiride treatment and one during liraglutide treatment Østoft S. H. et al. Diabetes Care 2014;37:1797-1805

  6. Østoft S. H. et al. Diabetes Care 2014;37:1797-1805

  7. Østoft S. H. et al. Diabetes Care 2014;37:1797-1805

  8. CONCLUSIONS • Six weeks of treatment with glimepiride or liraglutide lowered FPG and postprandial glucose excursions in patients with HNF1A diabetes • Glucose-lowering effect was greater with glimepiride at the expense of a higher risk of exclusively mild hypoglycemia Østoft S. H. et al. Diabetes Care 2014;37:1797-1805

  9. Østoft S. H. et al. Diabetes Care 2014;37:1797-1805

More Related